Recent Finacing
Recent Raise
Graviton Biosciences, a clinical-stage drug developer engineering ROCK2-targeted therapeutics, has lead candidate GV101 in studies and other inhibitors in preclinical development for fibrotic, inflammatory, autoimmune and neurologic indications.
